KR20010034477A - 상전이 촉매를 사용하여 n-치환된 헤테로시클릭 유도체를제조하는 방법 - Google Patents
상전이 촉매를 사용하여 n-치환된 헤테로시클릭 유도체를제조하는 방법 Download PDFInfo
- Publication number
- KR20010034477A KR20010034477A KR1020007008302A KR20007008302A KR20010034477A KR 20010034477 A KR20010034477 A KR 20010034477A KR 1020007008302 A KR1020007008302 A KR 1020007008302A KR 20007008302 A KR20007008302 A KR 20007008302A KR 20010034477 A KR20010034477 A KR 20010034477A
- Authority
- KR
- South Korea
- Prior art keywords
- organic solvent
- butyl
- methyl
- diazaspiro
- formula
- Prior art date
Links
- 239000003444 phase transfer catalyst Substances 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims description 28
- 125000000623 heterocyclic group Chemical class 0.000 title abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 239000003960 organic solvent Substances 0.000 claims description 24
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 10
- KWEQEHOPDHARIA-UHFFFAOYSA-N 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]phenyl]benzonitrile Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C#N)C(CCCC)=NC21CCCC2 KWEQEHOPDHARIA-UHFFFAOYSA-N 0.000 claims description 6
- GTLDIZREIXCKCF-UHFFFAOYSA-N 2-butyl-1,3-diazaspiro[4.4]nonan-4-one;hydrochloride Chemical compound Cl.N1C(CCCC)NC(=O)C11CCCC1 GTLDIZREIXCKCF-UHFFFAOYSA-N 0.000 claims description 6
- WLPATYNQCGVFFH-UHFFFAOYSA-N 2-phenylbenzonitrile Chemical compound N#CC1=CC=CC=C1C1=CC=CC=C1 WLPATYNQCGVFFH-UHFFFAOYSA-N 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000007529 inorganic bases Chemical class 0.000 claims description 6
- IPILPUZVTYHGIL-UHFFFAOYSA-M tributyl(methyl)azanium;chloride Chemical group [Cl-].CCCC[N+](C)(CCCC)CCCC IPILPUZVTYHGIL-UHFFFAOYSA-M 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 5
- WDBHYTAEQAWRCQ-UHFFFAOYSA-N 1-nonen-4-one Chemical compound CCCCCC(=O)CC=C WDBHYTAEQAWRCQ-UHFFFAOYSA-N 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 4
- -1 methoxy, ethoxy Chemical group 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000005862 Angiotensin II Human genes 0.000 description 7
- 101800000733 Angiotensin-2 Proteins 0.000 description 7
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 7
- 229950006323 angiotensin ii Drugs 0.000 description 7
- 229960002198 irbesartan Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 6
- 238000003408 phase transfer catalysis Methods 0.000 description 5
- 239000004305 biphenyl Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- LFFIEVAMVPCZNA-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]benzonitrile Chemical compound C1=CC(CBr)=CC=C1C1=CC=CC=C1C#N LFFIEVAMVPCZNA-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052987 metal hydride Inorganic materials 0.000 description 3
- 150000004681 metal hydrides Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000007126 N-alkylation reaction Methods 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 2
- 229940091173 hydantoin Drugs 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- VMQLILGAYAPXKA-UHFFFAOYSA-N 1,3-diazaspiro[4.4]non-1-en-4-one Chemical compound O=C1NC=NC11CCCC1 VMQLILGAYAPXKA-UHFFFAOYSA-N 0.000 description 1
- HZQLUIZFUXNFHK-UHFFFAOYSA-N 1-(bromomethyl)-4-phenylbenzene Chemical compound C1=CC(CBr)=CC=C1C1=CC=CC=C1 HZQLUIZFUXNFHK-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 230000010740 Hormone Receptor Interactions Effects 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003799 water insoluble solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims (12)
- 무기 염기 및 상전이 촉매의 존재하에 수불용성 유기 용매 중에서 하기 화학식 II의 2-R-1,3-디아자스피로[4.4]노난-4-온 히드로클로라이드를 하기 화학식 III의 4'-(할로메틸)[1,1'-비페닐]-2-카르보니트릴과 반응시키는 단계, 유기 용매를 분리시키는 단계, 유기 용매를 건조시키는 단계, 유기 용매를 여과시키는 단계, 여과된 유기 용매를 증발시켜 하기 화학식 I의 화합물을 얻는 단계, 하기 화학식 I의 화합물을 유기 용매로부터 결정화시키는 단계 및 임의로 화학식 I의 화합물을 그의 염으로 전환시키는 단계를 포함하는, 화학식 I의 화합물 또는 그의 염을 제조하는 방법.<화학식 I><화학식 II><화학식 III>식 중, R은 탄소수 1 내지 4의 저급 알킬 또는 탄소수 1 내지 3의 저급 알콕시이고, Hal은 염소, 브롬 또는 요오드이다.
- 제1항에 있어서, R이 메틸, 에틸, n-프로필, n-부틸, 메톡시, 에톡시 또는 프로폭시이고, Hal이 브롬인 방법.
- 제1항에 있어서, R이 n-부틸 또는 프로폭시이고, Hal이 브롬인 방법.
- 제1항에 있어서, 수불용성 유기 용매가 염화메틸렌 또는 톨루엔이고, 무기 염기가 수산화나트륨 또는 수산화칼륨인 방법.
- 제1항에 있어서, 상전이 촉매가 염화 메틸 트리부틸 암모늄인 방법.
- 제1항에 있어서, 반응이 실온에서 수행되는 방법.
- 제1항에 있어서, 화학식 I의 화합물이 메틸-tert-부틸 에테르로부터 결정화되는 방법.
- 제1항에 있어서, 염이 히드로클로라이드, 히드로브로마이드 또는 황산수소염인 방법.
- 무기 염기 및 상전이 촉매의 존재하에 수불용성 유기 용매 중에서 2-부틸-1,3-디아자스피로[4.4]노난-4-온 히드로클로라이드를 4'-(브로모메틸)[1,1'-비페닐]-2-카르보니트릴과 반응시키는 단계, 유기 용매를 분리시키는 단계, 임의로 유기 용매를 건조시키는 단계, 유기 용매를 여과시키는 단계, 여과된 유기 용매를 증발시켜 오일상 생성물을 얻는 단계, 이 오일상 생성물을 유기 용매로부터 결정화시켜 4'-[[2-부틸-4-옥소-1,3-디아자스피로[4.4]논-1-엔-3-일]메틸][1,1'-비페닐]-2-카르보니트릴을 얻는 단계 및 임의로 이를 그의 염으로 전환시키는 단계를 포함하는, 4'-[[2-부틸-4-옥소-1,3-디아자스피로[4.4]논-1-엔-3-일]메틸][1,1'-비페닐]-2-카르보니트릴 또는 그의 염을 제조하는 방법.
- 제9항에 있어서, 염이 히드로클로라이드, 히드로브로마이드 또는 황산수소염인 방법.
- 무기 염기 및 상전이 촉매의 존재하에 수불용성 유기 용매 중에서 2-부틸-1,3-디아자스피로[4.4]노난-4-온 히드로클로라이드를 4'-(브로모메틸)[1,1'-비페닐]-2-카르보니트릴과 반응시키는 단계, 유기 용매를 분리시키는 단계, 임의로 유기 용매를 건조시키는 단계, 유기 용매를 여과시키는 단계, 여과된 유기 용매를 증발시켜 오일상 생성물을 얻는 단계, 이 오일상 생성물을 유기 용매로부터 결정화시켜 4'-[[2-부틸-4-옥소-1,3-디아자스피로[4.4]논-1-엔-3-일]메틸][1,1'-비페닐]-2-카르보니트릴을 얻는 단계, 4'-[[2-부틸-4-옥소-1,3-디아자스피로[4.4]논-1-엔-3-일]메틸][1,1'-비페닐]-2-카르보니트릴을 2-부틸-3-[[2'-(1H-테트라졸-5-일)[1,1'-비페닐]-4-일]메틸]-1,3-디아자스피로[4.4]논-1-엔-4-온으로 전환시키는 단계 및 임의로 이를 그의 염으로 전환시키는 단계를 포함하는, 2-부틸-3-[[2'-(1H-테트라졸-5-일)[1,1'-비페닐]-4-일]메틸]-1,3-디아자스피로[4.4]논-1-엔-4-온 또는 그의 염을 제조하는 방법.
- 제11항에 있어서, 염이 히드로클로라이드, 히드로브로마이드 또는 황산수소염인 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7310398P | 1998-01-30 | 1998-01-30 | |
US60/073,103 | 1998-01-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010034477A true KR20010034477A (ko) | 2001-04-25 |
KR100546530B1 KR100546530B1 (ko) | 2006-01-26 |
Family
ID=22111745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007008302A KR100546530B1 (ko) | 1998-01-30 | 1999-01-20 | 상전이 촉매를 사용하여 n-치환된 헤테로시클릭 유도체를제조하는 방법 |
Country Status (15)
Country | Link |
---|---|
US (1) | US6162922A (ko) |
EP (1) | EP1060165B1 (ko) |
JP (2) | JP4441114B2 (ko) |
KR (1) | KR100546530B1 (ko) |
AT (1) | ATE275135T1 (ko) |
AU (1) | AU743018B2 (ko) |
CA (1) | CA2318791A1 (ko) |
DE (1) | DE69919849T2 (ko) |
DK (1) | DK1060165T3 (ko) |
ES (1) | ES2228006T3 (ko) |
HU (1) | HU226770B1 (ko) |
IL (1) | IL136357A (ko) |
PT (1) | PT1060165E (ko) |
TW (1) | TWI229076B (ko) |
WO (1) | WO1999038847A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101252309B1 (ko) * | 2004-08-23 | 2013-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | 이르베사르탄 및 그의 중간체의 제조 방법 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU218680B (hu) * | 1997-07-25 | 2000-10-30 | Sanofi-Synthelabo | Eljárás 1,3-diaza-spiro[4,4]non-1-én-4-on-származékok előállítására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek |
ATE340793T1 (de) * | 2002-07-16 | 2006-10-15 | Teva Pharma | Neue synthese von irbesartan |
WO2005051943A1 (en) * | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | Processes for the preparation of highly pure irbesartan |
EP1751123A4 (en) * | 2004-05-20 | 2010-06-30 | Reddys Lab Ltd Dr | PROCESS FOR PREPARING IRBESARTAN |
DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
SI21848A (sl) * | 2004-07-29 | 2006-02-28 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Priprava seskvihidratne hidrokloridne soli tetrazolskega derivata |
GB2419592A (en) * | 2004-10-26 | 2006-05-03 | Cipla Ltd | Process for the preparation of irbesartan hydrochloride |
ES2259909B1 (es) * | 2005-02-28 | 2007-06-16 | Inke, S.A. | Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de su intermedio de sintesis. |
EP1951714A1 (en) | 2005-07-27 | 2008-08-06 | Jubilant Organosys Limited | Process for producing 2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl- 4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one |
EP1764365A1 (en) * | 2005-09-20 | 2007-03-21 | KRKA, D.D., Novo Mesto | A process for the preparation of sartan derivates and intermediates useful in such process |
ATE517890T1 (de) * | 2006-04-07 | 2011-08-15 | Lek Pharmaceuticals | Verfahren zur herstellung von reinem irbesartan |
CN100413853C (zh) * | 2006-09-21 | 2008-08-27 | 浙江海正药业股份有限公司 | 厄贝沙坦的合成中间体及其制备方法和制备药物的用途 |
WO2008087401A1 (en) * | 2007-01-18 | 2008-07-24 | Rainbow Engineering Services | Sulfate salts of irbesartan and their preparation and pharmaceutical compositions |
US7671273B2 (en) | 2007-10-09 | 2010-03-02 | International Business Machines Corporation | Method and apparatus for facilitating signal transmission using differential transmission lines |
US8609859B2 (en) | 2009-04-08 | 2013-12-17 | Ctx Life Sciences Pvt. Ltd. | One pot process for preparing 2-butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro [4, 4] non-1-en-4-one (irbesartan) |
CN101781287B (zh) * | 2010-03-26 | 2013-03-20 | 天津大学 | 一种厄贝沙坦氢溴酸盐及其制备方法 |
CN110487931A (zh) * | 2019-08-21 | 2019-11-22 | 浙江华海药业股份有限公司 | 一种(e)-4-苯基-4-氧代-2-丁烯酸乙酯的分析方法 |
WO2022094148A1 (en) * | 2020-10-30 | 2022-05-05 | Encodia, Inc. | Conjugation reagents and methods using 1,2-cyclohexanediones |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
IE910913A1 (en) * | 1990-03-20 | 1991-09-25 | Sanofi Sa | N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them |
IL99372A0 (en) * | 1990-09-10 | 1992-08-18 | Ciba Geigy Ag | Azacyclic compounds |
US5126342A (en) * | 1990-10-01 | 1992-06-30 | Merck & Co., Inc. | Imidazole angiotensin ii antagonists incorporating acidic functional groups |
FR2673427B1 (fr) * | 1991-03-01 | 1993-06-18 | Sanofi Elf | Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
JPH06510762A (ja) * | 1991-08-19 | 1994-12-01 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | アンジオテンシン2受容体遮断イミダゾリノン誘導体 |
FR2688781B1 (fr) * | 1992-03-23 | 1994-07-01 | Sanofi Elf | Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
FR2689887B1 (fr) * | 1992-04-13 | 1995-06-23 | Sanofi Elf | Procede de preparation d'un derive de biphenyle. |
JP2707390B2 (ja) * | 1992-05-22 | 1998-01-28 | 壽製薬株式会社 | シクロヘプトイミダゾ−ル誘導体及びその製造方法並びにこれを含有する薬剤 |
US5612363A (en) * | 1995-06-02 | 1997-03-18 | Berlex Laboratories, Inc. | N,N-di(aryl) cyclic urea derivatives as anti-coagulants |
-
1999
- 1999-01-19 US US09/233,238 patent/US6162922A/en not_active Expired - Lifetime
- 1999-01-20 AT AT99904158T patent/ATE275135T1/de active
- 1999-01-20 ES ES99904158T patent/ES2228006T3/es not_active Expired - Lifetime
- 1999-01-20 DK DK99904158T patent/DK1060165T3/da active
- 1999-01-20 DE DE69919849T patent/DE69919849T2/de not_active Expired - Lifetime
- 1999-01-20 PT PT99904158T patent/PT1060165E/pt unknown
- 1999-01-20 JP JP2000530084A patent/JP4441114B2/ja not_active Expired - Lifetime
- 1999-01-20 IL IL13635799A patent/IL136357A/en not_active IP Right Cessation
- 1999-01-20 EP EP99904158A patent/EP1060165B1/en not_active Expired - Lifetime
- 1999-01-20 WO PCT/US1999/001201 patent/WO1999038847A1/en active IP Right Grant
- 1999-01-20 AU AU24615/99A patent/AU743018B2/en not_active Expired
- 1999-01-20 KR KR1020007008302A patent/KR100546530B1/ko not_active IP Right Cessation
- 1999-01-20 CA CA002318791A patent/CA2318791A1/en not_active Abandoned
- 1999-01-20 HU HU0100898A patent/HU226770B1/hu unknown
- 1999-01-26 TW TW088101130A patent/TWI229076B/zh not_active IP Right Cessation
-
2009
- 2009-10-28 JP JP2009247745A patent/JP2010018638A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101252309B1 (ko) * | 2004-08-23 | 2013-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | 이르베사르탄 및 그의 중간체의 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
JP2002501946A (ja) | 2002-01-22 |
ES2228006T3 (es) | 2005-04-01 |
AU743018B2 (en) | 2002-01-17 |
EP1060165A1 (en) | 2000-12-20 |
KR100546530B1 (ko) | 2006-01-26 |
JP2010018638A (ja) | 2010-01-28 |
TWI229076B (en) | 2005-03-11 |
DK1060165T3 (da) | 2004-11-22 |
HUP0100898A2 (hu) | 2002-02-28 |
EP1060165B1 (en) | 2004-09-01 |
HUP0100898A3 (en) | 2002-03-28 |
JP4441114B2 (ja) | 2010-03-31 |
DE69919849D1 (de) | 2004-10-07 |
EP1060165A4 (en) | 2002-07-31 |
AU2461599A (en) | 1999-08-16 |
PT1060165E (pt) | 2004-12-31 |
ATE275135T1 (de) | 2004-09-15 |
CA2318791A1 (en) | 1999-08-05 |
IL136357A (en) | 2004-07-25 |
WO1999038847A1 (en) | 1999-08-05 |
DE69919849T2 (de) | 2005-09-22 |
US6162922A (en) | 2000-12-19 |
HU226770B1 (en) | 2009-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100546530B1 (ko) | 상전이 촉매를 사용하여 n-치환된 헤테로시클릭 유도체를제조하는 방법 | |
CA2036304C (en) | Pyrimidinedione derivatives, their production and use | |
FI93957B (fi) | Menetelmä pyrimidiinien valmistamiseksi | |
RU2091376C1 (ru) | Производные тетразола | |
EP2176253B1 (en) | A process for the preparation or purification of olmesartan medoxomil or olmesartan medoxomil hydrohalide salt | |
EP1926705B3 (en) | Process for preparing valsartan | |
CZ20013907A3 (cs) | 1-(p-Thienylbenzyl)imidazoly jako agonisté receptorů angiotensinu-(1-7), způsob jejich přípravy, jejich pouľití a farmaceutické přípravky, které je obsahují | |
EA023029B1 (ru) | Способ получения 2-этокси-1-((2'-((гидроксиамино)иминометил)дифенил-4-ил)метил)-1h-бензо[d]имидазол-7-карбоновой кислоты и ее сложных эфиров | |
IE913773A1 (en) | Thienoimidazole derivatives, their production and use | |
BG107478A (bg) | Метод за кристализация на лозартан калий | |
US20090286989A1 (en) | Process for High Purity Anastrozole | |
EP2928472B1 (en) | Process for making reverse transcriptase inhibitors | |
US8106216B2 (en) | Process for the preparation of Irbesartan | |
CN114853741A (zh) | 一种新冠病毒主蛋白酶抑制剂的制备方法 | |
EP1984356B1 (en) | An improved process for the preparation of candesartan cilexetil | |
EP1899328B1 (en) | A process for the preparation of losartan derivatives by chlorination and reduction of the respective 1h-imidazole-5-carbaldehydes | |
US5274096A (en) | Hydrazine synthesis | |
CN115028589A (zh) | 一种阿齐沙坦工艺杂质的制备方法 | |
KR800001220B1 (ko) | 티아졸리닐 케토벤즈이미다졸 및 이의 유도체의 제조방법 | |
KR20200088570A (ko) | 피마살탄 및 그의 제조 중간체의 제조방법 | |
WO2005122699A2 (en) | An improved process for the preparation of n-substituted hetero cyclic derivatives | |
EP2343278A1 (en) | A process for preparing trisubstituted phenyl derivatives comprising a (1H-1,2,4-triazol-1-yl)alkyl group |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130107 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140103 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150106 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20151217 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20161220 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20171219 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 14 |
|
EXPY | Expiration of term |